Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002401206 | SCV002708098 | uncertain significance | Hereditary cancer-predisposing syndrome | 2020-08-31 | criteria provided, single submitter | clinical testing | The c.1629-4C>A intronic variant results from a C to A substitution 4 nucleotides upstream from coding exon 11 in the BRIP1 gene. This nucleotide position is poorly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. RNA studies have demonstrated that this alteration results in an incomplete splice defect; the clinical impact of this abnormal splicing is unknown at this time (Ambry internal data). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003097031 | SCV003477083 | likely benign | Familial cancer of breast; Fanconi anemia complementation group J | 2023-05-23 | criteria provided, single submitter | clinical testing | |
CHEO Genetics Diagnostic Laboratory, |
RCV003492763 | SCV004240386 | uncertain significance | Breast and/or ovarian cancer | 2022-06-30 | criteria provided, single submitter | clinical testing |